ICG-124 is under clinical development by ICell Gene Therapeutics and currently in Phase I for T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia). According to GlobalData, Phase I drugs for T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the ICG-124 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ICG-124 overview
Gene therapy is under development for the treatment of relapsed and/or refractory T-cell acute lymphoblastic leukemia and T-cell non-Hodgkin lymphoma. It is developed by using autologous CAR T technology. The therapy comprises of T cells genetically modified by lentiviral transduction to express a chimeric antigen receptor (CAR) targeting the antigen CD5.
ICell Gene Therapeutics overview
iCell Gene Therapeutics is a clinical-stage biotechnology company that develop chimeric antigen receptor (CAR) immunotherapeutic for the treat treatment of cancer and autoimmune diseases. The company platforms include T-cell targeted CARs, compound CARs and universal CARs for the indication of T-cell malignancies, acute myeloid leukemia (AML), lupus (SLE) and multiple sclerosis and solid tumor. ICell Gene Therapeutics It includes anti-CLL1and anti-CD33 compound for treating acute myeloid leukemia. It has operations in the US and China. ICell Gene is headquartered in Brookhaven, New York, the US.
For a complete picture of ICG-124’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
